Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor-Reference-Cited by-同舟云学术

Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor

Published:2008-03-01 Issue:3 Volume:93 Page:347-355
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Bruns I.,Steidl U.,Fischer J. C.,Czibere A.,Kobbe G.,Raschke S.,Singh R.,Fenk R.,Rosskopf M.,Pechtel S.,von Haeseler A.,Wernet P.,Tenen D. G.,Haas R.,Kronenwett R.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loss of CD34+ Cells and Effect of the Number of Viable Cryopreserved CD34+ Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. Comparison of CD34 + cell mobilization, blood graft cellular composition, and post‐transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: A prospective multicenter study;Transfusion;2021-09-09

3. Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial;BMC Cancer;2021-04-23

4. Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience;Frontiers in Immunology;2021-04-12

5. Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector cell therapy;Current Opinion in Hematology;2020-09-14